These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 27126995

  • 1. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R.
    Clin Cancer Res; 2016 Oct 15; 22(20):5109-5119. PubMed ID: 27126995
    [Abstract] [Full Text] [Related]

  • 2. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC, Chen A, Harrabi O, Sockolosky JT, Zhang A, Sangalang E, Doyle LV, Kauder SE, Fontaine D, Bollini S, Han B, Fu YX, Sim J, Pons J, Wan HI.
    J Hematol Oncol; 2020 Nov 30; 13(1):160. PubMed ID: 33256806
    [Abstract] [Full Text] [Related]

  • 3. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ, Bouchlaka MN, Hiebsch RR, Capoccia BJ, Donio MJ, Manning PT, Frazier WA, Karr RW, Pereira DS.
    Mol Cancer Ther; 2020 Mar 30; 19(3):835-846. PubMed ID: 31879362
    [Abstract] [Full Text] [Related]

  • 4. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
    Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, Rousseau F, Ferlin W, Kosco-Vilbois M, Fischer N, Masternak K.
    Mol Ther; 2017 Feb 01; 25(2):523-533. PubMed ID: 28153099
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.
    Oncotarget; 2017 Feb 14; 8(7):11284-11301. PubMed ID: 28061465
    [Abstract] [Full Text] [Related]

  • 7. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K.
    Eur J Cancer; 2017 May 14; 76():100-109. PubMed ID: 28286286
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, Zheng Y, Ring AM, Flavell RA, Weissman IL.
    Proc Natl Acad Sci U S A; 2017 Dec 05; 114(49):E10578-E10585. PubMed ID: 29158380
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E, Paradé M, Lutje Hulsik D, Spijkers S, Janssen W, Rens J, Reinieren-Beeren I, van den Tillaart G, van Duijnhoven S, Driessen L, Habraken M, van Zandvoort P, Kreijtz J, Vink P, van Elsas A, van Eenennaam H.
    J Immunother Cancer; 2019 Dec 04; 7(1):340. PubMed ID: 31801627
    [Abstract] [Full Text] [Related]

  • 13. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein α Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library.
    Wang Z, Hu N, Li X, Wang H, Ren C, Qiao C, Chen G, Wang J, Zhou L, Wu J, Zhang D, Feng J, Shen B, Peng H, Luo L.
    Mol Pharmacol; 2021 Sep 04; 100(3):193-202. PubMed ID: 34315811
    [Abstract] [Full Text] [Related]

  • 14. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
    Sim J, Sockolosky JT, Sangalang E, Izquierdo S, Pedersen D, Harriman W, Wibowo AS, Carter J, Madan A, Doyle L, Harrabi O, Kauder SE, Chen A, Kuo TC, Wan H, Pons J.
    MAbs; 2019 Sep 04; 11(6):1036-1052. PubMed ID: 31257988
    [Abstract] [Full Text] [Related]

  • 15. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
    Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K.
    Cancer Immunol Immunother; 2022 Feb 04; 71(2):473-489. PubMed ID: 34247273
    [Abstract] [Full Text] [Related]

  • 16. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A, Chen J.
    Trends Immunol; 2018 Mar 04; 39(3):173-184. PubMed ID: 29336991
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E, Lee EJ, Nam GH, Hong Y, Cho E, Yang Y, Kim IS.
    Biomaterials; 2017 Mar 04; 121():121-129. PubMed ID: 28086180
    [Abstract] [Full Text] [Related]

  • 20. Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.
    Li S, Chen D, Yang Y, Guo H, Liu D, Sun N, Bai X, Wang K, Li T, Li G, Yang C, Zhang W, Zhang L, Zhao G, Peng L, Liu S, Tu X, Zhang R, Tian W.
    Front Immunol; 2024 Mar 04; 15():1398508. PubMed ID: 38983860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.